[go: up one dir, main page]

MX2011011571A - Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia. - Google Patents

Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia.

Info

Publication number
MX2011011571A
MX2011011571A MX2011011571A MX2011011571A MX2011011571A MX 2011011571 A MX2011011571 A MX 2011011571A MX 2011011571 A MX2011011571 A MX 2011011571A MX 2011011571 A MX2011011571 A MX 2011011571A MX 2011011571 A MX2011011571 A MX 2011011571A
Authority
MX
Mexico
Prior art keywords
likelihood
gene expression
recurrence
chemotherapy
colorectal cancer
Prior art date
Application number
MX2011011571A
Other languages
English (en)
Inventor
Steven Shak
Drew Watson
Xitong Li
Lawrence Lee
Kim Langone
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX2011011571A publication Critical patent/MX2011011571A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En la presente se proporcionan ensayos moleculares basados en algoritmos que implican la medición de los niveles de expresión de genes pronóstico y/o predictivos, o de genes coexpresados de los mismos, a partir de una muestra biológica obtenida de un paciente con cáncer y el análisis de los niveles de expresión medidos para suministrar información relativa a la probabilidad de recidiva del cáncer colorrectal y/o la probabilidad de una respuesta positiva a la quimioterapia para el paciente. También se proporcionan métodos de análisis de los valores de expresión génica de los genes pronóstico y/o predictivos, así como métodos para identificar cocientes entre la expresión génica y la región del tumor, área superficial estromal asociada al tumor y cliques de genes, es decir, genes que se coexpresan con un biomarcador validado y, por consiguiente, pueden sustituirse por el marcador en un ensayo.
MX2011011571A 2009-05-01 2010-04-30 Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia. MX2011011571A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17489009P 2009-05-01 2009-05-01
US23942009P 2009-09-02 2009-09-02
PCT/US2010/033303 WO2010127322A1 (en) 2009-05-01 2010-04-30 Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy

Publications (1)

Publication Number Publication Date
MX2011011571A true MX2011011571A (es) 2012-02-13

Family

ID=43032592

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011571A MX2011011571A (es) 2009-05-01 2010-04-30 Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia.

Country Status (10)

Country Link
US (1) US10179936B2 (es)
EP (1) EP2425020A4 (es)
JP (2) JP2012525159A (es)
AU (1) AU2010242792B2 (es)
CA (1) CA2760333A1 (es)
IL (1) IL215991A (es)
MX (1) MX2011011571A (es)
NZ (1) NZ596054A (es)
SG (2) SG10201401722XA (es)
WO (1) WO2010127322A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2506066A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
CA2848463A1 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
KR20090003178A (ko) 2006-01-11 2009-01-09 게노믹 헬쓰, 인코포레이티드 직장결장암 예후에 대한 유전자 발현 마커
CN103495439B (zh) 2007-05-04 2015-09-16 欧普科诊断有限责任公司 流体连接器和微流体系统
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
AU2009246398A1 (en) * 2008-05-14 2009-11-19 Bristol-Myers Squibb Company Predictors of patient response to treatment with EGF receptor inhibitors
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
WO2010127322A1 (en) * 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US20120184454A1 (en) * 2011-01-14 2012-07-19 Kalady Matthew F Gene signature is associated with early stage rectal cancer recurrence
BR112013031019A2 (pt) 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
WO2012170710A1 (en) * 2011-06-08 2012-12-13 Altheadx Incorporated Disease classification modules
EP3312749B1 (en) * 2012-03-05 2024-05-01 OY Arctic Partners AB Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US11091809B2 (en) 2012-12-03 2021-08-17 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
ES2475366B1 (es) * 2012-12-10 2015-05-05 Fundación Imdea Alimentación Métodos y kits para el pronóstico del cáncer colorrectal
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US9672271B2 (en) 2013-05-17 2017-06-06 Lawrence Sirovich Method for identifying and employing high risk genomic markers for the prediction of specific diseases
CN103268431B (zh) * 2013-05-21 2016-07-06 中山大学 一种基于学生t分布的癌症亚型生物标志物检测系统
JPWO2015115544A1 (ja) * 2014-01-31 2017-03-23 学校法人順天堂 大腸がんの転移又は再発リスクの評価方法
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
FI3123381T3 (fi) 2014-03-28 2023-11-27 Opko Diagnostics Llc Eturauhassyövän diagnosointiin liittyviä koostumuksia ja menetelmiä
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
WO2016028141A1 (en) * 2014-08-18 2016-02-25 Universiti Kebangsaan Malaysia Method for determining prognosis of colorectal cancer
WO2016062892A1 (en) * 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334842B2 (en) * 2014-10-24 2022-02-17 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
EP3770274A1 (en) 2014-11-05 2021-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
CA2979559A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
WO2017002943A1 (ja) * 2015-07-01 2017-01-05 学校法人慶應義塾 癌組織の不均一性マーカー及びその使用
KR101936799B1 (ko) * 2017-01-09 2019-01-11 주식회사 엠이티라이프사이언스 구강전암의 치료용 약학 조성물 및 구강전암 또는 구강암의 예측 또는 진단 방법
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
AU2018361591B2 (en) * 2017-11-02 2024-10-10 Gc Corporation Intraoral examination method using information on bacterial group related to clinical indexes
US11335464B2 (en) * 2018-01-12 2022-05-17 Siemens Medical Solutions Usa, Inc. Integrated precision medicine by combining quantitative imaging techniques with quantitative genomics for improved decision making
EP3743534B1 (en) 2018-01-22 2022-03-23 Liquid Biopsy Research LLC Methods for colon cancer detection and treatment monitoring
WO2019204576A1 (en) * 2018-04-19 2019-10-24 The University Of Chicago Methods and kits for diagnosis and triage of patients with colorectal liver metastases
CA3099612C (en) * 2018-05-08 2023-01-17 F. Hoffmann-La Roche Ag Method of cancer prognosis by assessing tumor variant diversity by means of establishing diversity indices
CN112710856B (zh) * 2020-12-16 2022-12-02 江西省肿瘤医院(江西省癌症中心) 检测血清igf1蛋白的制剂在制备结直肠癌疗效监测试剂中的应用
CN113930506B (zh) * 2021-09-23 2022-10-18 江苏大学附属医院 一种预测肝细胞癌预后和治疗抵抗的谷氨酰胺代谢基因标签评分系统

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
AU4158799A (en) 1998-06-06 1999-12-30 Genostic Pharma Limited Probes used for genetic filing
CA2330929A1 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
EP1131470A4 (en) 1998-10-28 2004-11-10 Vysis Inc CELLULAR NETWORKS AND METHODS FOR DETECTION AND USE OF GENETIC DISORDER MARKERS
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
AU7721500A (en) * 1999-09-29 2001-04-30 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
CA2390687A1 (en) 1999-12-10 2001-06-14 Whitehead Institute For Biomedical Research Metastasis genes and uses thereof
AU2001276331A1 (en) 2000-04-06 2001-10-23 Epigenomics Ag Diagnosis of diseases associated with metastasis
WO2005000087A2 (en) 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii
WO2002012280A2 (en) 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030166064A1 (en) * 2000-08-03 2003-09-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002012328A2 (en) 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030077568A1 (en) * 2000-09-15 2003-04-24 Gish Kurt C. Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
US7105293B2 (en) 2000-09-19 2006-09-12 Whitehead Institute For Biomedical Research Genetic markers for tumors
AU2002246519A1 (en) * 2000-11-20 2002-08-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002074156A2 (en) * 2001-02-02 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030148314A1 (en) * 2001-08-01 2003-08-07 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US6964850B2 (en) * 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
WO2003041562A2 (en) * 2001-11-14 2003-05-22 Whitehead Institute For Biomedical Research Molecular cancer diagnosis using tumor gene expression signature
US20030148410A1 (en) * 2001-12-10 2003-08-07 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US20060046249A1 (en) * 2002-01-18 2006-03-02 Fei Huang Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways
US7955800B2 (en) * 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
EP1552293A4 (en) * 2002-09-10 2006-12-06 Guennadi V Glinskii METHOD FOR SEGREGATION OF GENES AND CLASSIFICATION OF BIOLOGICAL SAMPLES
WO2004110345A2 (en) 2002-10-29 2004-12-23 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
CA2506066A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
WO2005015236A2 (en) 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
EP1522594A3 (en) 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
US20060195266A1 (en) * 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
CA2562835A1 (en) 2004-04-16 2005-10-27 Monash University A method for monitoring the progress of cancer
EP1756309A2 (en) 2004-06-03 2007-02-28 Bayer HealthCare AG Methods for predicting and monitoring response to cancer therapy
WO2006010150A2 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
US20060183893A1 (en) 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells
JP2008535853A (ja) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌関連遺伝子
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
US20090215054A1 (en) 2005-12-13 2009-08-27 Carter Scott L Prognosis indicators for solid human tumors
NZ544432A (en) 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
KR20090003178A (ko) * 2006-01-11 2009-01-09 게노믹 헬쓰, 인코포레이티드 직장결장암 예후에 대한 유전자 발현 마커
WO2007112330A2 (en) 2006-03-24 2007-10-04 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of colon cancer
WO2007149965A2 (en) * 2006-06-22 2007-12-27 Wisconsin Alumni Research Foundation Stromal collagen in the diagnosis and characterization of breast cancer
CA2680591A1 (en) * 2007-03-15 2008-09-25 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US8067178B2 (en) * 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
AU2009246398A1 (en) * 2008-05-14 2009-11-19 Bristol-Myers Squibb Company Predictors of patient response to treatment with EGF receptor inhibitors
US9238747B2 (en) * 2008-11-17 2016-01-19 Basf Se Stain blocking compositions
US8765383B2 (en) * 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
WO2010127322A1 (en) * 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
US20110287958A1 (en) * 2010-05-20 2011-11-24 Steven Shak Method for Using Gene Expression to Determine Colorectal Tumor Stage
US20120046186A1 (en) * 2010-08-20 2012-02-23 Pelham Robert J Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs

Also Published As

Publication number Publication date
CA2760333A1 (en) 2010-11-04
NZ596054A (en) 2013-07-26
WO2010127322A1 (en) 2010-11-04
IL215991A (en) 2016-09-29
JP2016104014A (ja) 2016-06-09
US10179936B2 (en) 2019-01-15
JP2012525159A (ja) 2012-10-22
SG10201401722XA (en) 2014-08-28
US20100285980A1 (en) 2010-11-11
AU2010242792B2 (en) 2015-06-11
EP2425020A1 (en) 2012-03-07
AU2010242792A1 (en) 2011-11-17
SG175832A1 (en) 2011-12-29
IL215991A0 (en) 2012-01-31
EP2425020A4 (en) 2016-04-20

Similar Documents

Publication Publication Date Title
MX2011011571A (es) Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia.
MX2018011725A (es) Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
Bradford et al. Molecular markers of prostate cancer
NO20083461L (no) Genekspresjonsmarkorer for kolorektal cancer-prognose
WO2010096154A3 (en) Compositions and methods for diagnosis and prognosis of colorectal cancer
ATE526333T1 (de) Reagentien zum nachweis von hypochloriger säure
WO2010129937A3 (en) Methods for detecting genetic variations in dna samples
WO2008115419A3 (en) Gene expression markers for prediction of patient response to chemotherapy
WO2009057113A3 (en) Diagnosis and prognosis of specific cancers by means of differential detection of micro-rnas/mirnas
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
WO2010005991A3 (en) Circulating tumor and tumor stem cell detection using genomic specific probes
CY1114993T1 (el) Προφιλ εκφρασης γονιδιου για να προβλεπονται εκβασεις καρκινου μαστου
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
MX2010005960A (es) Biomarcadores de braf.
EP2619587A4 (en) BIOMARKER FOR PREDICTING THE REPRODUCTION OF A COLORECTAL CARCINOMA
GB2451985A (en) Sepsis detection microarray
WO2008128043A3 (en) Diagnostic and prognostic methods for renal cell carcinoma
AR078584A1 (es) Identificacion de microarn (miarn) en muestras fecales como biomarcador de canceres gastroenterologicos
WO2010034794A3 (en) Methods and kits for the diagnosis and the staging of colorectal cancer
Kim et al. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer
EP2475789A4 (en) METHODS FOR PREDICTING SENSITIVITY OF DISEASE OR DISORDER TO RECEPTOR TYROSINE KINASE INHIBITOR THROUGH MUTATION ANALYSIS IN PIK3CA GENE
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
WO2008061527A3 (de) Prognostische marker für die klassifizierung von kolorektalen karzinomen basierend auf expressionsprofilen von biologischen proben
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal

Legal Events

Date Code Title Description
FG Grant or registration